What's Happening?
The U.S. Food and Drug Administration (FDA), specifically its Center for Drug Evaluation and Research (CDER), is offering a research fellowship in Bioinformatics and Omics Biomarker Discovery. This opportunity is within the Office of Translational Sciences
(OTS), Office of Clinical Pharmacology (OCP), Division of Applied Regulatory Science (DARS) in Silver Spring, Maryland. The fellowship aims to integrate new scientific advancements into the regulatory review process, focusing on biomarker discovery using large-scale proteomics data. The selected fellow will be involved in the statistical analysis of omics data to identify clinically meaningful biomarkers for disease progression, treatment efficacy, and patient stratification in clinical trials. This includes quality control, statistical modeling, multivariate analysis, pathway analysis, data visualization, and manuscript preparation. The goal is to develop qualified regulatory tools and support informed regulatory decision-making for drug development.
Why It's Important?
This FDA fellowship is crucial for advancing drug development and regulatory science in the United States. By focusing on bioinformatics and omics biomarker discovery, the FDA is investing in cutting-edge research that can lead to more precise and effective treatments. The development of robust biomarkers can significantly improve the efficiency and success rates of clinical trials, ultimately bringing safer and more effective drugs to market faster. This initiative helps bridge the gap between scientific innovation and medical product review, ensuring that regulatory processes keep pace with technological advancements. The outcomes of this research could benefit pharmaceutical companies by providing clearer guidelines for drug development and patients by offering more targeted therapies and improved diagnostic tools.
What's Next?
Applications for the fellowship are being reviewed on a rolling basis, with an anticipated appointment start date that is flexible. The initial appointment will be for one year, with potential for renewal based on FDA recommendations and funding availability. The fellow will contribute to ongoing research projects, with learning objectives focused on performing quality control, designing statistical analyses, applying advanced statistical and machine learning methods, conducting systems-level analyses, and interpreting omics data within the regulatory science framework. The research is expected to lead to scientific manuscripts and contribute to the dissemination of regulatory research, potentially influencing future biomarker qualification standards and drug development guidelines.
